(Health Korea News / Yu Ji-in) JW Pharmaceutical will participate in the global phase 4 clinical trial for the hair care cosmetic product ‘DUCRAY NEOPTIDE EXPERT’ from French global pharmaceutical company Pierre Fabre.
Ducray Neoptide Expert is a hair care cosmetic product from Pierre Fabre, France, that was launched through high-level research and development and human application testing. JW Shinyak signed an exclusive domestic supply contract with Pierre Fabre and began full-scale domestic sales in January of this year.
The global phase 4 clinical trial is a clinical trial that will be conducted for 6 months from September of this year to March 2025 to follow-up on the efficacy and improve safety of ‘Ducray Neoptide Expert’. It is scheduled to be conducted simultaneously in 15 countries around the world, including Europe, Asia, the Middle East, South America, and Africa, and in Korea, JW Shinyak will be in charge of this phase 4 clinical trial.
JW Shinyak is in charge of this Korean clinical trial, and three institutions, the Korean Society of Hair Restoration, the Korean Society of Hair Restoration, and the Korean Society of Dermatologists, are participating together. They plan to conduct research on a total of approximately 200 subjects who require follow-up care for their scalp and hair after hair loss treatment at five major university hospitals and 15 specialized clinics in Korea.
This phase 4 clinical trial targets subjects who are in stage 3 (the stage where hair loss progression is visible) of the Norwood Hamilton classification. JW Shinyak plans to comprehensively confirm the research results, including the improvement of the scalp after using hair care cosmetics and the follow-up effects on the scalp and hair after hair loss treatment due to other factors, through this 6-month clinical trial.
A JW Pharmaceutical official said, “This global phase 4 clinical trial is an opportunity to prove the excellent hair care effects of ‘Ducray Neoptide Expert’ worldwide,” and added, “We will continue to make efforts in various ways so that hair care cosmetics can establish themselves as a solid choice for consumers and patients who are concerned about hair care.”
JW Shinyak has a diverse portfolio of hair loss treatments that can be prescribed depending on the cause of hair loss, such as heredity, childbirth, and seborrheic dermatitis. It has ‘Monad Tablets’ and ‘Monastar Tablets’, which contain ‘finasteride’ as the main ingredient, and ‘Dutamoa Tablets’, which contain ‘dutasteride’ as the main ingredient, as oral hair loss treatments. In March of last year, through an exclusive sales contract with Galderma Korea, it began domestic distribution and sales of ‘El-Cranel Alpha Liquid (Alphatradiol),’ an original hair loss treatment topical agent that can be used for both men and women’s hair loss, thereby expanding its hair loss treatment lineup.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
